Med BioGene - Corporate Information

Corporate Information Leadership Team

Featured News

September 04, 2014

Med BioGene Announces Receipt of Proxies for Upcoming Annual and Special Meeting

August 29, 2014

Med BioGene Reports Financial Results for Q2 2014

August 21, 2014

Med BioGene Responds to Assertions Made by Dissident Shareholder

August 15, 2014

Med BioGene Provides Update and Announces Proposed Financing

August 06, 2014

Med BioGene Announces Director Nominations and Postponement of Annual and Special Meeting

March 24, 2014

Med BioGene Announces Regulatory Approval of GeneFx® Lung

Home

About Us

Corporate Information

Med BioGene Inc. (MBI) is a life science company based in Vancouver, British Columbia, that is currently focused on managing the license and rights to GeneFx® Lung (formerly, LungExpress Dx), a proprietary gene expression-based test for early-stage non-small-cell lung cancer. GeneFx Lung is expected to provide better-informed and personalized treatment decisions to assist in the selection of patients for adjuvant chemotherapy. MBI has partnered with Precision Therapeutics for the global commercialization of GeneFx Lung. MBI's common shares are traded on the TSX Venture Exchange. For more information regarding MBI, please visit www.medbiogene.com. For more information regarding Precision, please visit www.precisiontherapeutics.com.